Rectal Cancer Clinical Trials 2024

What are the top hospitals conducting rectal cancer research?

When it comes to advancing the treatment options for rectal cancer, several top hospitals across the United States are leading the way. In Houston, M D Anderson Cancer Center is making significant strides with eight active clinical trials dedicated to rectal cancer and a total of 23 completed trials. This pioneering institution initiated its first trial in 2000, demonstrating their longstanding commitment to finding innovative solutions for this disease. Meanwhile, in New york City's Memorial Sloan Kettering Cancer Center, researchers are actively engaged in six ongoing rectal cancer trials while having accomplished 16 previous studies since recording their initial trial back in 1999.

Notably contributing from Arizona's medical landscape is Mayo Clinic located in Scottsdale where alongside treating patients they maintain around six cutting-edge clinical tests concerning rectal cancer which will potentially lead medical professionals towards better understanding of such cases along with previously aiding ten researches; Their interest can be traced back a little over a decade ago when they commenced examining this intricate condition through collaborative investigation all done by engaging various participants under controlled environment.They have come up as prominent contributors focused on vertical advancement of fighting against an ailment like Rectum related cancers

Furthermore adding value to this cause is California’s City of Hope Medical Center situated at Duarte whose committed team showcases continued support through conducting four ongoing investigations specific specifically aimed addressing subjects predominantly falling under domain of treating individuals suffering from diseases confined majorly restricted within these lower gastrointestinal areas ,alongside already conducted thirteen experiments till date starting from year two thousand seven until now.

Lastly but not least Washington University School Of Medicine Located In Saint Louis caters similar objectives.Last but not least,is evident through its contribution via conducting four distinct scientific examinations particularly focusing upon concerns pertaining to ailments rooted ceasing solely limited within these lower parts regionally positioned along digestive tract ;And have achieved notable results so far as stated by numbers showcasing nineteen successful already concluded assignments finalizing after initiating very first one somewhere during early months beginning year two thousand two

These hospitals collectively represent the forefront of medical research and innovation in the quest to combat rectal cancer. Their dedication to clinical trials not only offers hope to individuals affected by this condition but also paves the way for improved treatment options and outcomes on a global scale. Through their tireless efforts, they are advancing our understanding of rectal cancer and working towards finding better solutions that will enhance the lives of patients worldwide

Which are the best cities for rectal cancer clinical trials?

When it comes to rectal cancer clinical trials, several cities show promising progress in research and treatment options. Los Angeles, California leads with 29 active trials focusing on medications like Encorafenib, Pembrolizumab, and Subprotocol C2 for MET exon 14 deletion/mutation. New york, New York follows closely behind with 18 ongoing studies investigating treatments such as Oxaliplatin and Amivantamab for participants with Rectal Adenocarcinoma. Nashville, Tennessee and Houston, Texas both have 16 active trials each exploring fruquintinib plus best supportive care and Cetuximab among other treatment approaches. Lastly, Sacramento, California offers 14 active trials attempting to evaluate the efficacy of Pembrolizumab and 5-Fluorouracil (5-FU). These cities serve as hubs for cutting-edge rectal cancer clinical research that strives to improve patient outcomes through innovative interventions.

Which are the top treatments for rectal cancer being explored in clinical trials?

Rectal cancer research is constantly evolving, with several promising treatments currently being explored in clinical trials. The top contenders in the field include:

• Cetuximab: This drug is being tested in three active trials for rectal cancer. With 14 all-time trials since its introduction in 2004, it shows great potential.
• Pembrolizumab: Another hopeful treatment, pembrolizumab is involved in two ongoing rectal cancer trials and has been part of five all-time studies since 2016.
• Chemotherapy: Widely used as a standard treatment approach, chemotherapy remains an active area of investigation with two current rectal cancer trials and a total of twelve all-time studies conducted since 2012.
• Regorafenib: Also showing promise, regorafenib is participating in two active rectal cancer trials and has been studied in five previous research endeavors starting from 2015.

These treatments offer new avenues for improving outcomes and bringing hope to patients battling rectal cancer.

What are the most recent clinical trials for rectal cancer?

Exciting progress is being made in the field of rectal cancer research, with several recent clinical trials offering hope for improved treatment options. One trial focuses on dose-finding for non-small cell lung cancer (NSCLC) in relation to rectal cancer. Another study explores the combination of pembrolizumab and regorafenib as a potential therapy. Additionally, researchers are investigating the tolerability and effectiveness of TAS-102, oxaliplatin, irinotecan with bevacizumab for rectal cancer patients. Dostarlimab monotherapy and botensilimab/balstilimab therapy also show promise as potential treatments for this challenging disease. These ongoing trials hold significant potential to enhance outcomes and quality of life for individuals affected by rectal cancer.

What rectal cancer clinical trials were recently completed?

Promising strides in rectal cancer research have been made through several recently concluded clinical trials. In July 2018, Klus Pharma Inc.'s A166 trial reached completion, shedding light on new possibilities for treatment. Mayo Clinic's investigation into the Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102 wrapped up in December 2017, providing valuable insights into its potential efficacy against this type of cancer. Additionally, Wake Forest University Health Sciences' examination of 6,8-bis(benzylthio)octanoic acid came to a close in January 2015. These studies reflect the dedication and ongoing efforts within scientific communities to advance our understanding and management of rectal cancer.